US20100068157A1 - Oral compositions, their preparation and use - Google Patents

Oral compositions, their preparation and use Download PDF

Info

Publication number
US20100068157A1
US20100068157A1 US12/374,447 US37444707A US2010068157A1 US 20100068157 A1 US20100068157 A1 US 20100068157A1 US 37444707 A US37444707 A US 37444707A US 2010068157 A1 US2010068157 A1 US 2010068157A1
Authority
US
United States
Prior art keywords
composition
water
mixture
composition according
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/374,447
Other languages
English (en)
Inventor
Ian Ripley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oraident Ltd
Oraldent Ltd
Original Assignee
Oraident Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oraident Ltd filed Critical Oraident Ltd
Assigned to ORALDENT LIMITED reassignment ORALDENT LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIPLEY, IAN, THOMAS, HOWARD
Assigned to ORALDENT LIMITED reassignment ORALDENT LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIPLEY, IAN, THOMAS, HOWARD
Publication of US20100068157A1 publication Critical patent/US20100068157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to flavonoid-containing compositions for use in the preparation of oral compositions, such as toothpastes, mouthwashes or dental rinses.
  • oral compositions comprising an antibacterial bioflavonoid stock solution, their preparation and use.
  • flavonoids having antimicrobial, particularly anti-bacterial and especially anti-viral, activity
  • flavonoids covers a large variety of differing compounds, which may be made available by extraction from various natural sources. Depending on both the source and the nature or method of extraction, the overall chemical composition of the resulting flavonoid mixture can itself vary widely. Individual flavonoids can vary greatly in their biological activity (or be inactive), both in terms of toxicity and effectiveness against microbes such as viruses and bacteria. Therefore, in combination, such flavonoids can also vary in their biological activity.
  • WO 02/47615 discloses an oral composition comprising an organoleptically suitable carrier and a terpenoid and/or a flavonoid dispersed in the carrier;
  • DE 19949575 discloses a combination of fluorides and flavonoids for treating dental disorders and preventing caries; and JP62051613 relates to a dentifrice composition containing 0.001-0.1 wt % flavonoid compound(s) selected from flavonol, chrysin, hesperetin and hesperidin.
  • None of the prior art formulations disclose a combination of a bioflavonoid composition (itself comprising a particular combination of water-soluble flavonoid components) with one or more water-soluble fruit acid(s) in an amount and form suitable for oral administration as a solution, and having anti-bacterial activity.
  • the present invention provides an oral composition having a pH in the range of from 3 to 8.5, preferably 3.5 to 8, preferably 4 to 7, more preferably 5 to 6.5, comprising:
  • the oral composition comprises in the range of from 0.1 to 5% w/w of the stock solution, more preferably from 0.1 to 2% w/w, such as about 1%.
  • the oral composition comprises in the range of from 20 to 80% w/w water, towards the lower end of that range in the case of a toothpaste and towards the upper end for a liquid composition such as a mouthwash/rinse/spray.
  • a paste may comprise in the range of from 20 to 45% w/w water, such as 20 to 30% w/w, particularly if silica is included in component (c), and a liquid formulation may comprise in the range of from 60 to 80% w/w water (all w/w based on the total weight of the oral composition).
  • the stock solution is preparable from water-soluble bioflavonoids in combination with a fruit acid, such as citric, malic and ascorbic acids.
  • a fruit acid such as citric, malic and ascorbic acids.
  • One or more of the acids are preferably neutralized with a suitable base, such as a quaternary ammonium base, for example a choline base, such as choline carbonate, bicarbonate or, preferably, hydroxide.
  • a suitable base such as a quaternary ammonium base, for example a choline base, such as choline carbonate, bicarbonate or, preferably, hydroxide.
  • citric, malic and ascorbic acids are all used in the preparation of the composition, and especially preferred is when these are fully neutralized to provide citrate, malate and/or ascorbate salts.
  • choline ascorbate is especially preferred. Accordingly, it is preferred that the stock solution is substantially free from fruit acids, by which is meant that its pH is around neutral
  • Exemplary pH ranges for the stock solution are from 3 to 8.5, 3.5 to 8.5, 3.5 to 8, 4 to 8, 4 to 7.5, 4.5 to 7.5, 4.5 to 7, 5 to 7, 5 to 6.5, 5.5 to 6.5 and 5.5 to 6, the pH being for example about 5, about 5.5, about 6, about 6.5 or about 7.
  • a preferred stock solution comprises water-soluble bioflavonoids and choline ascorbate (present either as choline base (eg hydroxide) and ascorbic acid or as the salt per se).
  • the stock solution preferably further comprises a non-toxic solvent, such as a water-miscible or hydrophilic solvent, and more preferably comprises water and a water-miscible co-solvent such as glycerine, a polyhydric alcohol or the like.
  • a non-toxic solvent such as a water-miscible or hydrophilic solvent
  • the solvent comprises a water/glycerine mixture, preferably in the ratio of from 2:1-1:2 (water:co-solvent).
  • components (b) and (c) are alcohol-, especially ethanol-, free.
  • the stock solution preferably is preparable from:
  • Ingredient % (w/w) Ingredient in Stock Solution Bioflavonoid mixture 1-20, preferably 2 to 15, more preferably (45% in biomass) 3 to 15, such as 3, 4, or 15, most preferred is 3.3.
  • Citric acid 1-20 preferably 4 to 15, such as 4, 5, 10, or 15, most preferred is 4.5.
  • Malic acid 1-20 preferably 4 to 15, such as 4, 5, 10, or 15, most preferred is 4.5.
  • Ascorbic acid (vitamin C)* 1-20 preferably 1 to 5*, such as 1, 2, 3, 4, or 5, most preferred is 1.5.
  • Choline hydroxide solution 1-45 preferably 4 to 20*, such as 5, 8, (45% in water)* 10, 12, 15, or 18.
  • Glycerine/water or other Balance qv to 100%, preferably 5-50*, solvent(s) such as 7, 10, or 15, most preferred is 7.5.
  • solvent(s) such as 7, 10, or 15
  • glycerine and water or alternative solvent(s)
  • the solvent comprises approximately equal % of both glycerine and water, such as 5 to 25% each, such as 15% glycerine and 20% water (when choline is present as the hydroxide solution), or such as 25% glycerine and 25% water (when the choline and ascorbic acid are present as 5% choline ascorbate).
  • the oral compositions of the present invention preferably are preparable from (based on the weight of the oral composition):
  • the oral compositions of the present invention are preparable from (based on the weight of the oral composition):
  • the oral compositions of the present invention more preferably are preparable from:
  • preferred oral compositions of the present invention comprise in the order of 1% w/w of the stock solution, in one embodiment, preferred oral compositions of the invention are preparable from:
  • most preferred oral compositions of the invention are preparable from:
  • most preferred oral compositions of the invention are preparable from:
  • the stock solution is prepared by processes known to those skilled in the art.
  • the co-solvents are mixed with the water at ambient temperature and then the acids involved in neutralization processes, such as ascorbic acid, are blended together with the solvent at an increased temperature, which is kept low enough to ensure no degradation of any of the ingredients.
  • the temperature is kept in the range of from about 25 to below 55 degC and is preferably in the region of 50 degC.
  • the remaining acids preferably, citric and malic
  • the bioflavonoids are added, followed by the bioflavonoids, resulting in a solution having a pH in the range of from about 2.0 to 6.5 but typically is from about 2.2 to 3.5, especially in the range of from 2.3 to 3.0.
  • the remaining un-neutralised acids are also substantially neutralized, for example, by choline hydroxide, to result in a substantially neutral solution having a pH in the range of, for example, from 5 to 8.5, preferably 5.5 to 7, more preferably 5.5 to 6.5.
  • the stated antimicrobial effect of prior art formulations comprising a bioflavonoid relies on the inhibition by the bioflavonoid of the uptake of essential amino acids in the cytoplasmic membrane of the microbe, such as by inhibiting the viral neuroamidase.
  • the formulations of the present invention are believed to be effective because the combination of selected soluble bioflavonoids with choline ascorbate results in encapsulation of the microbe, breakdown of the flavonone and glucoside components into independent fragments, and subsequent deactivation of the microbe by the flavonone fragments and choline ascorbate.
  • the bioflavonoid mixture comprises water-soluble bioflavonoids in association with biomass resulting from the extraction process; accordingly, the bioflavonoid mixture may be associated with up to 40-60% w/w, preferably about 55% w/w, biomass (based on the weight of the bioflavonoid mixture).
  • the bioflavonoids are preferably glucosides, especially those selected from isocriocirm, isonaringin, narangin, hesperidin, neohesperidin, neodiomin, naringenin, poncirin and rhiofolen, and more preferably each of these is present in the mixture.
  • the major part of the bioflavonoid mixture comprises narangin and neohesperidin, such as when these comprise in excess of 75% of the bioflavonoid component (excluding biomass).
  • bioflavonoids such as flavonol, chrysin, hesperetin
  • the bioflavonoid component therefore consists essentially of the water-soluble bioflavonoids listed hereinabove, although trace amounts of other bioflavonoids may be present.
  • the water-soluble bioflavonoids comprise the following percentages (by weight of bioflavonoid in the total bioflavonoid component):
  • HPLC 45 A suitable source of such a water-soluble bioflavonoid mixture is herein referred to as ‘HPLC 45’, of which about 45% (of the total composition of HPLC 45) comprises such bioflavonoids, with the balance (about 55%) comprising biomass such as pectins, sugars and minor organic acids.
  • biomass such as pectins, sugars and minor organic acids.
  • the major part of the bioflavonoid mixture comprises narangin and neohesperidin, such as when these comprise in excess of 35% of the bioflavonoid component in a mixture with biomass such as HPLC 45.
  • the following bioflavonoids are preferably present:
  • the HPLC 45 is available from Exquim (the food arm of Grupo Ferrer) as Citrus Bioflavonoid Complex 45% HPLC. It is derived from a starting material comprised of the pith of immature, bitter (blood/red) oranges such as Seville oranges that are classed as ‘inedible’ and from which the pips, flesh and oily skin have been substantially removed or remain undeveloped. This starting material is crushed in a hydrophilic, ionic solvent such as water or water/alcohol mixtures, preferably water/ethanol in a ratio of about 1:10-20 (solvent: starting material). The resulting mixture is filtered to leave a water-soluble biomass, which is retained, and an insoluble biomass, which is discarded. The water-soluble biomass is then subject to fine filtration, after which it is flash-distilled to leave a brown, hygroscopic powder (HPLC 45).
  • Exquim the food arm of Grupo Ferrer
  • Citrus Bioflavonoid Complex 45% HPLC It is derived from
  • the bioflavonoid mixture for use in the oral compositions of the present invention is distinguishable particularly by comprising water-soluble glucosides from the mixture obtained from grapefruit or other citrus fruits or other plant sources, which comprise water-insoluble flavonoids; and, more preferably, is distinguishable from the mixture obtained when substantial amounts of the seeds, pulp and/or flesh of such fruits are comprised in the starting material, which particularly comprise water-insoluble components.
  • the more developed/mature starting material of the prior art is more likely to have been subjected to pesticides and/or synthetic fertilizing media, and are therefore less ‘organic’ or pure in their origin than the bioflavonoid mixture of the solutions of the present invention.
  • the stock solution comprises 1-20%, preferably 2 to 15%, more preferably 3 to 15%, such as 3, 4, or 15, most preferred is 3.3% w/w of the HPLC45.
  • the stock solution preferably comprises 0.45-9%, preferably 0.9 to 6.75%, more preferably 1.35 to 6.75%, such as 1.35, 1.8, or 6.75, most preferred is 1.485% of the bioflavonoid mixture.
  • the oral composition and, particularly in the absence of other ingredients except water, the stock solution has a pH of from about 3 to about 8.5, more preferably of from about 4 to 7.5, such as about 5 to 7; especially preferred is when the pH is about 5.5 to 6.5.
  • the oral composition is substantially free of hydrogen ions, such as from fruit acids; the fruit acids used in the preparation of the stock solution and/or oral composition therefore having been substantially neutralised, preferably as described above by addition of a base to the stock solution.
  • the oral composition also comprises a buffering agent
  • the pH of the stock solution can vary outside these ranges provided that the buffering agent is present in an amount effective to provide the oral composition with a pH within these ranges.
  • component (c) of the oral compositions of this invention may comprise a buffering agent to regulate or adjust the pH of the final composition, such as an alkali metal hydroxide or ammonium hydroxide or a mono-, di- or tri-basic phosphate such as a tri(alkali metal) phosphate.
  • a buffering agent to regulate or adjust the pH of the final composition, such as an alkali metal hydroxide or ammonium hydroxide or a mono-, di- or tri-basic phosphate such as a tri(alkali metal) phosphate.
  • a buffering agent to regulate or adjust the pH of the final composition
  • a mono-, di- or tri-basic phosphate such as a tri(alkali metal) phosphate.
  • the phosphates are preferably incorporated in the form of their sodium, potassium or ammonium salts; more preferably, sodium salts are employed. However, in cases where hypertensive effects of sodium ions are of concern, mono- and di-potassium phosphates may be used.
  • the buffering agent is disodium phosphate, for example, it may be present up to about 5% w/w of the oral composition, preferably in the range of from 0 to 0.5%, such as about 0.05% w/w.
  • Another optional ingredient, component (c), may comprise a source of fluoride, such as sodium fluoride or sodium monofluorophosphate, up to about 0.5% w/w of the oral composition.
  • the fluoride source is preferably in the range of from 0 to 0.15%, such as about 0.05% w/w in the case of liquid compositions but more in the case of toothpastes, where from 0 to 0.3%, such as around 0.24%, w/w or in the range of from 0 to 1500 ppm (as fluoride ions) is suitable.
  • compositions of the invention may be present in the oral compositions of the invention, such as flavouring, sweetening or colouring agents, or preservatives.
  • Mint such as from peppermint or spearmint, cinnamon, eucalyptus, citrus, cassia, anise and menthol are examples of suitable flavouring agents.
  • Flavouring agents are preferably present in the oral compositions in an amount in the range of from 0 to 3%; preferably up to 2%, such as up to 0.5%, preferably around 0.2%, in the case of liquid compositions; but optionally more in the case of toothpaste, preferably 0.5 to 2%, more preferably around 1% w/w.
  • Sweeteners include artificial or natural sweetening agents, such as sodium saccharin which may be present in an amount in the range of from 0 to 2%, preferably up to 1% w/w, such as 0.05 to 0.3% w/w of the oral composition.
  • Colouring agents are suitable natural or synthetic colours, such as titanium dioxide or CI 42090, or mixtures thereof. Colouring agents are preferably present in the oral compositions in an amount in the range of from 0 to 3%; preferably up to 0.1%, such as up to 0.05%, preferably around 0.005-0.0005%, in the case of liquid compositions; but optionally more in the case of toothpaste, preferably up to 1%, more preferably around 0.5% w/w.
  • sodium benzoate is preferred in concentrations insufficient substantially to alter the pH of the oral composition, otherwise the amount of buffering agent may need to be adjusted to arrive at the desired pH.
  • component (c) may include other active agents such as anti-plaque agents and/or antimicrobial agents.
  • Suitable agents include quaternary ammonium compounds such as domiphen bromide, cetyl pyridinium chloride (CPC), phenolic compounds, ethanol, and the preservatives mentioned above.
  • Such active agents may be present in an amount in the range of from 0 to 4% w/w but may be as much as 70%, such as up to 30%, in the case of ethanol.
  • CPC or the like is preferably present up to 2%, such as about 0.05% w/w, especially in liquid oral compositions of the invention.
  • Ethanol may comprise as much as 70%, preferably about 0 to 30% w/w in liquid compositions of the invention, such as about 15% w/w in a mouthspray, but preferred oral compositions of the invention are those wherein ethanol or any other alcohol is substantially absent.
  • component (c) may include humectants, surfactants (non-ionic, cationic or amphoteric), thickeners, gums and binding agents.
  • Suitable humectants include glycerine, xylitol, glycerol and glycols such as propylene glycol, which may be present in an amount of up to 50% w/w each, but total humectant is preferably not more than about 60-80% w/w of the oral composition.
  • liquid oral compositions may comprise up to about 30% glycerine plus up to about 5%, preferably about 2% w/w xylitol.
  • Surfactants are preferably not anionic and may include polysorbate 20 or cocoamidobetaine or the like in an amount up to about 6%, preferably about 1.5 to 3%, w/w of the oral composition.
  • the oral compositions of the invention are in the form of a mouthspray, it is preferred to include a film-forming agent up to about 3% w/w of the oral composition, such as in the range of from 0 to 0.1%, preferably about 0.001 to 0.01%, such as about 0.005% w/w of the oral composition.
  • Suitable film-formers include sodium hyaluronate and those sold under the tradename Gantrez.
  • the oral compositions of the invention are in the form of toothpaste, it is preferred to include gums, binders and/or thickeners, such as colloidal silica, carrageenan and cellulose derivatives such as sodium carboxymethylcellulose.
  • Such ingredients may be present in an amount up to about 3% w/w of the oral composition, such as up to about 2%, preferably about 0.5 to 1%, w/w of the oral composition.
  • Toothpaste compositions of this invention may also comprise an abrasive agent, such as hydrated silica, dicalcium phosphate, or water-insoluble alkali metal metaphosphates, up to about 25% w/w and preferably in the range of from about 10 to about 15% w/w of the oral composition.
  • an abrasive agent such as hydrated silica, dicalcium phosphate, or water-insoluble alkali metal metaphosphates, up to about 25% w/w and preferably in the range of from about 10 to about 15% w/w of the oral composition.
  • compositions of the present invention may be prepared by any method known in the art for the formulation of similar compositions, such as a toothpaste, mouthwash or rinse, mouthspray, or the like. All methods comprise bringing the components (a) and (b) and, if present, (c) together in intimate physical admixture.
  • the compositions are packaged in suitable packaging such as a plastics or metallic tube, plastics or glass transparent, translucent or opaque bottle, jar or dispenser, with or without spray or other applicator means, together with instructions for use.
  • suitable packaging such as a plastics or metallic tube, plastics or glass transparent, translucent or opaque bottle, jar or dispenser, with or without spray or other applicator means, together with instructions for use.
  • Such packaging may itself be further packaged into a cardboard box or other suitable container and the same or further instructions for use may be inserted therein or inscribed thereon; suitably, such instructions may be inscribed on a pack insert or leaflet.
  • the packaging preferably lists the active, main or all ingredients of the composition.
  • the instructions may include those known to the person skilled in the art of oral compositions, particularly those for anti-bacterial use.
  • they may recommend that a pea-sized amount of toothpaste be applied to the dentition at regular intervals, 2-3 times per day; that a mouthful of mouthwash or rinse be sluiced around the oral cavity at least once per day and preferably after meals; and the like.
  • the oral compositions of the present invention may therefore be useful for treating, preventing or ameliorating the effects of a microbial, especially a bacterial, infection in the oral cavity or other periodontal disease; for cleaning, disinfecting or removing debris from the oral cavity; for refreshing, freshening, removing or improving the odour or taste in the oral cavity; and for generally attending to the hygiene, appearance and feel of the oral cavity.
  • the present invention further provides a stock solution comprising a mixture of bioflavonoids and fruit acids (such as the mixture hereinbefore described) in the preparation of a medicament for the treatment of a microbial, especially a bacterial, infection in the oral cavity; in particular, wherein the medicament comprises in the range of from 0.1% to 10% w/w (based on the total weight of the oral composition) of the stock solution.
  • the present invention provides (a) a stock solution comprising a mixture of bioflavonoids and fruit acids together with (c) other pharmaceutically or pharmacologically acceptable ingredients suitable for oral administration (such as those described hereinbefore), in the preparation of a medicament for the treatment of a microbial, especially a bacterial, infection in the oral cavity; in particular, wherein the medicament comprises in the range of from 0.1% to 10% w/w (based on the total weight of the oral composition) of the stock solution.
  • the oral compositions of the present invention are useful in the treatment or prevention of infections, disease or conditions arising from the following bacteria: Actinomyces odontolyticus, Actinomyces viscosus, Porphyromonas gingivalis, Prevotella intermedia, Prevotella buccae, Prevotella dentalis, Streptococcus gordonii, Streptococcus sanguinis, S oralis, S sobrinus, S mutans, S intermedius, Lactobacillus acidophilus, Eubacterium nodatum, Actinomyces israelii, Actinomyces naeslundii, C albicans and C tropicalis .
  • Example 1 In biological tests, a stock solution (see Example 1) used in the preparation of the oral compositions of this invention was found to be inhibitory of all the above-mentioned bacteria at 1/10 dilution and the above-mentioned non-Streptococcal bacteria were also inhibited at 1/100 dilution. Other biological data are given in the Examples hereinbelow. The present invention will now be illustrated by the following non-limiting examples.
  • the starting material comprises the pith of immature, bitter (blood/red) oranges such as Seville oranges that are classed as ‘inedible’ and from which the pips, flesh and oily skin have been substantially removed.
  • the starting material is milled and then crushed in water or water/ethanol in a ratio of about 1:10-20 (solvent: starting material).
  • the resulting mixture is filtered to leave a water-soluble biomass, which is retained, and an insoluble biomass, which is discarded.
  • the water-soluble biomass is then subject to fine filtration, after which it is flash-distilled to leave a brown, hygroscopic powder (HPLC 45).
  • the HPLC 45 is available from Exquim (Grupo Ferrer).
  • a mouthspray according to the invention was prepared as follows, using the above-noted ingredients: In vessel (A) disperse the sodium hyaluronate in the water with stirring to give a lump free solution. Add the sodium saccharin, cetyl pyridinium chloride, disodium phosphate, xylitol and stock solution and stir until all the ingredients are fully dissolved. Add the glycerine and mix until homogeneous. In a separate vessel (B) combine the polysorbate 20, flavour and ethanol. Mix until the flavour is fully dispersed. Add the contents of vessel (B) to vessel (A) with stirring to give a homogeneous liquid.
  • a mouthspray according to the invention may be prepared as follows, using the above-noted ingredients: In vessel (A) disperse the sodium hyaluronate in the glycerine. With stirring, add the water to give a lump free solution. Add the xylitol, stock solution, sodium saccharin, cetyl pyridinium chloride and disodium phosphate, and stir until all the ingredients are fully dissolved. In a separate vessel (B) combine the polysorbate 20, flavour and ethanol. Mix until the flavour is fully dispersed. Add the contents of vessel (B) to vessel (A) with stirring to give a homogeneous liquid.
  • A. Laboratory Sample An oral rinse according to the invention was prepared as follows, using the above-noted ingredients: In mixing vessel (A) combine the water, sodium saccharin, sodium fluoride, disodium phosphate, colour(s), xylitol and stock solution and mix until all ingredients are fully dissolved. Add the glycerine and mix until homogeneous. In a separate vessel (B) combine the polysorbate 20 and flavour. Mix until the flavour is fully dispersed. Add the contents of vessel (B) to vessel (A) with stirring to give a homogeneous liquid.
  • An oral rinse according to the invention was prepared as follows, using the above-noted ingredients: In mixing vessel (A) combine the water, humectant(s), stock solution, sodium saccharin, sodium fluoride, disodium phosphate and colour. Mix until all ingredients are fully dissolved. In a separate vessel (B) combine the polysorbate 20, flavour and ethanol. Mix until the flavour is fully dispersed. Add the contents of vessel (B) to vessel (A) with stirring to give a homogeneous liquid.
  • a toothpaste according to the invention was prepared as follows, using the above-noted ingredients: Combine water and glycerine in vessel A. To this add the sodium saccharin, sodium fluoride, stock solution and xylitol and stir to dissolve. Transfer the contents of vessel A to a vacuum mixer (vessel B). Preblend the powders (hydrated silicas, xanthan gum and titanium dioxide) in vessel C and add to the liquid phase in the vacuum mixer (B). Mix under vacuum until homogeneous. Add the surfactant and flavour to the vacuum mixer (B) and mix under vacuum to form a smooth paste.
  • a toothpaste according to the invention was prepared as follows, using the above-noted ingredients: In a vacuum mixer, disperse the xanthan gum in the glycerine with stirring. Add the water to the dispersion and mix until the xanthan gum is fully hydrated and the mixture lump free. Add the stock solution, water and humectants) in a vacuum mixer. Add the soluble salts (i.e. sodium saccharin, sodium fluoride) to the liquid phase. Blend the powders (i.e. silica and titanium dioxide) and add to the mixer. Stir to form a uniform dispersion. Add the surfactant and flavour, and mix under vacuum to form a smooth paste.
  • soluble salts i.e. sodium saccharin, sodium fluoride
  • Bioflavonoid mix 3.3% Malic acid 4.5% Citric acid 4.5% Choline ascorbate 6.0% LFG61 alkyl glycoside 13.3% Propylene glycol 7.5% Water 60.9% Ph of solution 1.5 to 1.75
  • Tests were carried out to determine whether oral compositions of the invention were active against a range of anaerobes and facultative bacteria that are implicated in periodontal disease.
  • the bacteria used were Actinomyces odontolyticus, Actinomyces viscosus, Porphyromonas gingivalis, Prevotella intermedia, Prevotella buccae, Prevotella dentalis, Streptococcus gordonii and Streptococcus sanguinis . All were ATCC-type strains.
  • All the anaerobes were grown in Fastidious Anaerobic Broth (FAB) at 37deg C for 24 h in a Don Whitely Anaerobic Chamber (available from Don Whitely, Yorkshire, UK).
  • the facultative bacteria were grown in nutrient broth in 10% (v/v) carbon dioxide at 37deg C. for 24 h.
  • the starter culture was 1 ml of an overnight growth containing approximately 10 6 cfu/ml.
  • the cultures were supplemented with stock solution of the invention in concentrations down to 1/10,000 (0.001%); the diluent was the appropriate broth. Growth was estimated by a spectrophotometric increase in absorption at 650 nm.
  • Percentages refer to those of stock solution present in the respective formulations.
  • Toothpaste v Cultures Organism 0.5% 1% A viscosus 1/5000 1/5000 A odontolyticus 1/1000 1/1000 P gingivalis 1/5000 1/5000 P intermedia 1/1000 1/1000 P buccae 1/5000 1/5000 P denticola 1/5000 1/5000 S gordonii 1/1000 1/1000 S sanguinis 1/1000 1/1000
  • Mouthwash v Culture Organism 0.5% 1% A viscosus 1/10,000 1/10,000 A odontolyticus 1/5000 1/5000 P gingivalis 1/10,000 1/10,000 P intermedia 1/1000 1/1000 P buccae 1/1000 1/5000 P denticola 1/5000 1/5000 S gordonii 1/5000 1/5000 S sanguinis 1/5000 1/5000
  • Toothpaste v Well Diffusion Organism 0.5% 1% A viscosus 1/10,000 1/10,000 A odontolyticus 1/5000 1/5000 P gingivalis 1/10,000 1/10,000 P intermedia 1/1000 1/1000 P buccae 1/1000 1/1000 P denticola 1/5000 1/5000 S gordonii 1/5000 1/5000 S sanguinis N/A N/A
  • Example 5 Two formulations were tested: Example 5 and Example 6. Ranges of two-fold dilutions were prepared for each formulation, having a pH of 1.75 and 2.0, respectively, using either Blood-Heart Infusion (BHI) or Sabouraud's broth as the diluent, giving solutions with a range of concentrations (8%-0.015625% Stock Solution, v/v).
  • BHI Blood-Heart Infusion
  • Sabouraud's broth as the diluent
  • each microbial suspension was added to the wells of a microtitre plate.
  • An equal volume of the solution of either Example 5 or Example 6 (containing the matching broth) was added to each well, giving final concentrations of Stock Solution of 4%-0.0078125% (v/v).
  • Wells were also prepared containing no Stock Solution and/or no microorganism, to act as controls.
  • Each microtitre plate was incubated for 24 h at 37° C. under the appropriate atmospheric conditions. After incubation the relative amounts of each microbial species were estimated by measuring the turbidity in each well using a spectrophotometer reading absorbance at a wavelength of 544 nm. Absorbance readings were blanked using the controls with an absence of microorganisms.
  • MIC Minimal Inhibitory Concentration
  • Example 5 The growth of each of the microorganisms studied was inhibited by both formulations of Example 5 and Example 6, with the exception of Candida glabrata . This yeast species' growth did not appear to be inhibited at all by Example 6 even when it was present at a concentration of 8% (v/v), the highest concentration used in this study.
  • Example 5 was more effective than Example 6 at inhibiting microbial growth.
  • the MIC for each microorganism was lower with Example 5 than Example 6, with the exception of Porphyromonas gingivalis for which both formulations had an equal value of 1%.
  • Example 5 inhibited the growth of each microorganism when at a concentration of 1% (v/v), even if the reduction of growth was not quite >50% (the criterion set in this study to define the MIC). This supports the use of 1% (v/v) of the stock solution of Example 5 as the preferred working concentration in future products and research.
  • Example 5 Actinomyces odontolyticus 0.015625 2 Actinomyces viscosus 2 4 Clostridium difficile 1 2 Porphyromonas gingivalis 1 1 Prevotella buccae 2 4 Prevotella intermedia 2 4 Streptococcus gordonii 0.03125 2 Streptococcus sanguinis 0.03125 2 Candida albicans 0.125 8 Candida glabrata 0.0625 >8* Candida krusei 0.015625 2 Candida parapsilosis 0.03125 8 Candida tropicalis 0.0625 8 *No inhibition of growth apparent, even with highest concentration used in this study

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US12/374,447 2006-07-20 2007-07-20 Oral compositions, their preparation and use Abandoned US20100068157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0614353.1 2006-07-20
GBGB0614353.1A GB0614353D0 (en) 2006-07-20 2006-07-20 Oral compositions, their preparation and use
PCT/GB2007/002758 WO2008009958A1 (en) 2006-07-20 2007-07-20 Oral compositions, their preparation and use

Publications (1)

Publication Number Publication Date
US20100068157A1 true US20100068157A1 (en) 2010-03-18

Family

ID=36998354

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/374,443 Active 2029-08-17 US9532939B2 (en) 2006-07-20 2007-07-20 Combinations for oral compositions, their preparation and use
US12/374,447 Abandoned US20100068157A1 (en) 2006-07-20 2007-07-20 Oral compositions, their preparation and use
US15/247,806 Active US9987214B2 (en) 2006-07-20 2016-08-25 Combinations for oral compositions, their preparation and use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/374,443 Active 2029-08-17 US9532939B2 (en) 2006-07-20 2007-07-20 Combinations for oral compositions, their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/247,806 Active US9987214B2 (en) 2006-07-20 2016-08-25 Combinations for oral compositions, their preparation and use

Country Status (9)

Country Link
US (3) US9532939B2 (zh)
EP (2) EP2043593B1 (zh)
JP (3) JP5452221B2 (zh)
CN (2) CN101495089B (zh)
AT (2) ATE548020T1 (zh)
CA (2) CA2658710C (zh)
ES (2) ES2385405T3 (zh)
GB (2) GB0614353D0 (zh)
WO (2) WO2008009958A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055053A1 (en) * 2006-07-20 2010-03-04 Oraldent Limitied Combinations for oral compositions, their preparation and use
US10499637B2 (en) 2009-11-02 2019-12-10 Meda Ab Compositions comprising flavonoid-containing extracts from plants of the genus citrus and/or isolated citrus flavonoids and specific cationic surface active agents, and said composition for use as an agent for treating infestations with head lice

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803473D0 (en) * 2008-02-26 2008-04-02 Stephenson Group Ltd Sanitising composition
WO2009106890A2 (en) * 2008-02-26 2009-09-03 Stephenson Group Limited Preserved product; and preservative composition
US9056121B1 (en) * 2008-06-30 2015-06-16 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteophytes
IT1396468B1 (it) * 2008-11-11 2012-12-14 Farma Derma Srl Uso topico di acido ialuronico ad azione filmogena in preparati per il trattamento e profilassi di patologie delle vie respiratorie.
EP2198862A1 (en) 2008-12-18 2010-06-23 Citrox Limited Use of flavonoids to treat parasitic infection
CN102300552A (zh) * 2009-02-03 2011-12-28 太阳星光齿磨公司 含有桔皮苷的组合物
GB2468836B (en) 2009-02-05 2012-09-05 Citrox Biosciences Ltd Sterilisation with misting
ES2713349T3 (es) * 2009-04-15 2019-05-21 Bmg Pharma S P A Composiciones de sal mineral-ácido sulfónico y procedimientos de uso
JP2011073970A (ja) * 2009-09-29 2011-04-14 Sunstar Inc 口腔用又は咽喉用組成物
EP2635120A1 (en) * 2010-08-06 2013-09-11 Phyto Innovative Products Ltd Compositions comprising oleuropeins and flavanoids and their use
CN102652712A (zh) * 2011-03-04 2012-09-05 全球生技股份有限公司 具抗菌的口腔护理组成物及其制法
WO2012139146A1 (de) * 2011-04-13 2012-10-18 Technische Universität Wien Verfahren zur bekämpfung von bakteriellen infektionen bei einer pflanze unter verwendung von flavonoiden
US9387969B2 (en) * 2011-04-14 2016-07-12 Edward Schapiro Toothpaste composition and method of applying a single serving of toothpaste to a toothbrush
HUE049844T2 (hu) 2011-06-13 2020-11-30 Oraldent Ltd Szemészeti készítmények
EP2681996A1 (en) * 2012-07-03 2014-01-08 CeBeC Group Ltd. Biocidal compositions
CA2881408C (en) 2012-08-24 2021-10-12 Citrox Biosciences Limited Bioflavonoid impregnated materials
DE102013000699A1 (de) * 2012-10-04 2014-04-10 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung, insbesondere pharmazeutische Zusammensetzung, insbesondere zur Verabreichung bei Heiserkeit
JP6118547B2 (ja) * 2012-12-10 2017-04-19 花王株式会社 口腔用組成物
CN104853734B (zh) * 2012-12-20 2020-05-22 高露洁-棕榄公司 含有离子性液体的口腔护理组合物
RU2652131C2 (ru) * 2013-06-27 2018-04-25 Фирмениш Са Вкусомодифицирующий ингредиент
RU2673473C2 (ru) * 2013-12-27 2018-11-27 Колгейт-Палмолив Компани Пребиотические композиции для ухода за полостью рта, содержащие карбоновые кислоты
NO339503B1 (no) * 2014-06-18 2016-12-19 Meda Otc Ab Sammensetning for forebygging eller behandling av dental erosjon
CN106446599A (zh) * 2015-08-11 2017-02-22 中国科学院青岛生物能源与过程研究所 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法
RU2624502C2 (ru) * 2015-11-17 2017-07-04 Общество с ограниченной ответственностью "ДЖИ-Групп" Лечебно-профилактический материал для стоматологии
CN107028839A (zh) * 2017-05-31 2017-08-11 易金阳 口腔护理组合物及其应用、牙膏组合物
GB201713362D0 (en) * 2017-08-21 2017-10-04 Givaudan Sa Improvements in or relating to organic compounds
WO2019232031A1 (en) * 2018-05-29 2019-12-05 Mary Kay Inc. Topical compositions and methods
JP2020002019A (ja) * 2018-06-25 2020-01-09 ロート製薬株式会社 口腔用組成物
GB2578147A (en) * 2018-10-18 2020-04-22 Oraldent Ltd Bioflavonoid compositions and their use
GB2578146A (en) 2018-10-18 2020-04-22 Citrox Biosciences Ltd Bioflavonoid compositions and their use for water purification and food preservation
CN109369805A (zh) * 2018-12-27 2019-02-22 广东工业大学 一种用于防治牙龈炎的卵黄抗体夹心含片及其制备方法
JP2020200245A (ja) * 2019-06-06 2020-12-17 ポッカサッポロフード＆ビバレッジ株式会社 口臭抑制用組成物
EP3982913A1 (en) 2019-06-14 2022-04-20 The Procter & Gamble Company Leave-on oral care compositions
WO2020248229A1 (en) * 2019-06-14 2020-12-17 The Procter & Gamble Company Leave-on oral care compositions
JP7237207B2 (ja) 2019-06-14 2023-03-10 ザ プロクター アンド ギャンブル カンパニー 洗い流さない口腔ケア組成物
EP3982917A1 (en) 2019-06-14 2022-04-20 The Procter & Gamble Company Leave-on oral care compositions
IT201900025483A1 (it) * 2019-12-24 2021-06-24 Adco S R L Composizione per la disinfezione della cavità orale
WO2022157314A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid for use on the skin
GB2605972A (en) 2021-04-19 2022-10-26 Citrox Biosciences Ltd Nutritional supplements for amelioration of respiratory tract infections
GB2605971A (en) 2021-04-19 2022-10-26 Citrox Biosciences Ltd Nutritional supplement and uses
EP4444418A1 (de) 2021-12-09 2024-10-16 Beiersdorf AG Topisch applizierbare zubereitung zur verbesserung des hautzustandes
CN115518004B (zh) * 2022-01-13 2024-01-16 海尼达(江苏)医疗科技有限公司 一种辅助改善口腔健康的组合物及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2823166A (en) * 1954-11-17 1958-02-11 Walter H Hoffman Choline ascorbate, methods for producing same, and compositions thereof
US2888381A (en) * 1955-09-01 1959-05-26 Us Vitamin Corp Solutions of citrus bioflavonoids
US5571518A (en) * 1995-10-30 1996-11-05 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing tricholine citrate
US5728391A (en) * 1994-12-05 1998-03-17 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid and its salt for treating skin diseases
US6120779A (en) * 1998-01-29 2000-09-19 Soma Technologies Use of partial and complete salts of choline and carboxylic acids for the treatment of skin disorders
US20020114730A1 (en) * 2000-12-06 2002-08-22 Darlene Jazzar Lemon extract and treatment methods
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20030017219A1 (en) * 2001-05-25 2003-01-23 Frank Corsini Carbohydrate modifying agent and drinks containing the modifying agent
US6706256B2 (en) * 2001-05-15 2004-03-16 The Procter & Gamble Co. Oral care compositions
US20040157800A1 (en) * 2001-06-25 2004-08-12 Antonietta Buononato Ascorbyl derivatives of carnitines and cosmetic compositions containing same
US20050215493A1 (en) * 2002-05-01 2005-09-29 Masaki Miyake Calcium-containing tissue strengthening agents and use thereof
US20060018860A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
US20060034784A1 (en) * 2004-08-12 2006-02-16 The Procter & Gamble Company Oral compositions and systems
US20070053851A1 (en) * 2003-09-09 2007-03-08 Maillan Philippe E Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances
US20100055053A1 (en) * 2006-07-20 2010-03-04 Oraldent Limitied Combinations for oral compositions, their preparation and use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55125840A (en) 1979-03-19 1980-09-29 Olympus Optical Co Endoscope
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPH0755895B2 (ja) 1985-08-29 1995-06-14 サンスター株式会社 歯磨組成物
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
JPH07187974A (ja) * 1993-12-24 1995-07-25 Lion Corp 口腔用組成物
JPH10182390A (ja) * 1996-12-25 1998-07-07 Lion Corp 口腔用組成物
DE19949575A1 (de) 1999-10-14 2001-04-19 Michael Hermann Hinz Neuartige Wirkstoffkombination von biologisch hochwirksamen Fluoriden u. Flavonoiden zur Therapie und Prphylaxe von Zahnerkrankungen
JP4261744B2 (ja) * 2000-07-05 2009-04-30 小林製薬株式会社 口腔用組成物
WO2002047615A2 (en) * 2000-12-13 2002-06-20 University Of Rochester Oral compositions and use thereof
JP2002226386A (ja) * 2001-01-30 2002-08-14 Rohto Pharmaceut Co Ltd 植物抽出物を含有する外皮用組成物
JP2003055179A (ja) * 2001-08-10 2003-02-26 Hideaki Hanaki 口腔スプレー用組成物
JP4846141B2 (ja) 2001-08-31 2011-12-28 東洋精糖株式会社 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
WO2003097078A1 (en) 2002-05-15 2003-11-27 Zhishin Inc. Nutraceutical compositions comprising citrus alkaloids and method
US7545801B2 (en) * 2002-12-02 2009-06-09 Cedar Point Communications, Inc. In-band control mechanism for switching architecture
KR101095258B1 (ko) * 2002-12-19 2011-12-20 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 조성물에 있어서의 수분의 변동을 억제하는 방법과 그 용도
JP4904811B2 (ja) * 2003-02-13 2012-03-28 株式会社林原生物化学研究所 α，α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤
DE10323178A1 (de) * 2003-05-22 2004-12-09 Basf Ag Mischung, umfassend ein Tensid und ein Cotensid
JP2005132792A (ja) * 2003-10-31 2005-05-26 Univ Kinki 抗掻痒剤
JP4030495B2 (ja) * 2003-10-31 2008-01-09 学校法人近畿大学 抗アレルギー剤
JP2005170804A (ja) * 2003-12-08 2005-06-30 Univ Kinki 抗アレルギー剤
FR2869229B1 (fr) * 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
EP1703409A1 (en) 2004-07-21 2006-09-20 Sony Corporation Content processing device, content processing method, and computer program
JP3665327B1 (ja) 2004-09-24 2005-06-29 小林製薬株式会社 消臭剤
US20060140881A1 (en) * 2004-12-22 2006-06-29 Guofeng Xu Oral care compositions containing flavonoids and flavans
JP4654060B2 (ja) * 2005-03-29 2011-03-16 株式会社 ア・ファーマ近大 ネオヘスペリジンの抗酸化作用に基づく美白剤または色素沈着症改善剤
US7629011B2 (en) * 2005-08-22 2009-12-08 Del Monte Corporation Process for removing the peel from citrus fruit

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2823166A (en) * 1954-11-17 1958-02-11 Walter H Hoffman Choline ascorbate, methods for producing same, and compositions thereof
US2888381A (en) * 1955-09-01 1959-05-26 Us Vitamin Corp Solutions of citrus bioflavonoids
US5728391A (en) * 1994-12-05 1998-03-17 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid and its salt for treating skin diseases
US5571518A (en) * 1995-10-30 1996-11-05 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing tricholine citrate
US6120779A (en) * 1998-01-29 2000-09-19 Soma Technologies Use of partial and complete salts of choline and carboxylic acids for the treatment of skin disorders
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20020114730A1 (en) * 2000-12-06 2002-08-22 Darlene Jazzar Lemon extract and treatment methods
US6706256B2 (en) * 2001-05-15 2004-03-16 The Procter & Gamble Co. Oral care compositions
US20030017219A1 (en) * 2001-05-25 2003-01-23 Frank Corsini Carbohydrate modifying agent and drinks containing the modifying agent
US20040157800A1 (en) * 2001-06-25 2004-08-12 Antonietta Buononato Ascorbyl derivatives of carnitines and cosmetic compositions containing same
US20050215493A1 (en) * 2002-05-01 2005-09-29 Masaki Miyake Calcium-containing tissue strengthening agents and use thereof
US20070053851A1 (en) * 2003-09-09 2007-03-08 Maillan Philippe E Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances
US20060018860A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
US20060034784A1 (en) * 2004-08-12 2006-02-16 The Procter & Gamble Company Oral compositions and systems
US20100055053A1 (en) * 2006-07-20 2010-03-04 Oraldent Limitied Combinations for oral compositions, their preparation and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cvetnic, Acta Pham. 54, pages 243-250, 2004 *
Nogata et al. (Already of record, submitting a clearer copy.) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055053A1 (en) * 2006-07-20 2010-03-04 Oraldent Limitied Combinations for oral compositions, their preparation and use
US9532939B2 (en) 2006-07-20 2017-01-03 Ricerfarma S.R.L. Combinations for oral compositions, their preparation and use
US9987214B2 (en) 2006-07-20 2018-06-05 Oraldent Limited Combinations for oral compositions, their preparation and use
US10499637B2 (en) 2009-11-02 2019-12-10 Meda Ab Compositions comprising flavonoid-containing extracts from plants of the genus citrus and/or isolated citrus flavonoids and specific cationic surface active agents, and said composition for use as an agent for treating infestations with head lice

Also Published As

Publication number Publication date
CN101495089B (zh) 2019-06-11
CN101495090A (zh) 2009-07-29
CN101495090B (zh) 2015-04-22
JP5452221B2 (ja) 2014-03-26
US9532939B2 (en) 2017-01-03
JP2014074062A (ja) 2014-04-24
CA2658468A1 (en) 2008-01-24
JP2009544604A (ja) 2009-12-17
ATE551988T1 (de) 2012-04-15
ATE548020T1 (de) 2012-03-15
EP2043592B1 (en) 2012-03-07
EP2043593B1 (en) 2012-04-04
WO2008009956A1 (en) 2008-01-24
GB2440440A (en) 2008-01-30
CN101495089A (zh) 2009-07-29
EP2043592A1 (en) 2009-04-08
US20100055053A1 (en) 2010-03-04
WO2008009958A1 (en) 2008-01-24
JP5883428B2 (ja) 2016-03-15
CA2658710A1 (en) 2008-01-24
GB0714228D0 (en) 2007-08-29
US20160361346A1 (en) 2016-12-15
ES2384687T3 (es) 2012-07-11
ES2385405T3 (es) 2012-07-24
JP5508005B2 (ja) 2014-05-28
EP2043593A1 (en) 2009-04-08
CA2658710C (en) 2016-07-05
GB0614353D0 (en) 2006-08-30
US9987214B2 (en) 2018-06-05
CA2658468C (en) 2017-05-23
JP2009544603A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
CA2658468C (en) Oral compositions, their preparation and use
US10918580B2 (en) Oral care compositions and methods
RU2416391C1 (ru) Композиция для ухода за полостью рта
JP5893324B2 (ja) メチルメルカプタン抑制剤
JP2010270045A (ja) 液体口腔用組成物
CN103458864A (zh) 液体口腔用组合物以及稳定化混合该组合物中组分的方法
EP2399576B1 (en) Use of antibacterial compounds for the oral cavity hygiene
KR100637653B1 (ko) 구취억제용 구강용 조성물
JPH04164021A (ja) 口腔用組成物
KR100659139B1 (ko) 항균력이 우수한 구강용 조성물
WO2024143126A1 (ja) 口腔用組成物
KR20240078208A (ko) 사과 추출물을 유효성분으로 포함하는 구강 미생물에 대한 항균 및 치아 미백용 조성물
KR20050010082A (ko) 은 치약 및 그 제조방법
KR20070102184A (ko) 항균력이 우수한 구강용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORALDENT LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIPLEY, IAN;THOMAS, HOWARD;REEL/FRAME:023723/0902

Effective date: 20090220

AS Assignment

Owner name: ORALDENT LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIPLEY, IAN;THOMAS, HOWARD;REEL/FRAME:023860/0760

Effective date: 20090220

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION